R H P Hilgers1, J G R De Mey. 1. Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands.
Abstract
BACKGROUND AND PURPOSE: We tested the hypothesis that activated arterial smooth muscle (ASM) stimulates endothelial vasomotor influences via gap junctions and that the significance of this myoendothelial coupling increases with decreasing arterial diameter. EXPERIMENTAL APPROACH: From WKY rats, first-, second-, third- and fourth-order branches of the superior mesenteric artery (MA1, MA2, MA3 and MA4 respectively) were isolated and mounted in wire-myographs to record vasomotor responses to 0.16-20 micromol x L(-1) phenylephrine. KEY RESULTS: Removal of endothelium increased the sensitivity (pEC(50)) to phenylephrine in all arteries. The nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) (100 micromol x L(-1)) did not modify pEC(50) to phenylephrine in all denuded arteries, and increased it in intact MA1, MA2 and MA3 to the same extent as denudation. However, in intact MA4, the effect of L-NAME was significantly larger (DeltapEC(50) 0.57 +/- 0.02) than the effect of endothelium removal (DeltapEC(50) 0.20 +/- 0.06). This endothelium-dependent effect of L-NAME in MA4 was inhibited by (i) steroidal and peptidergic uncouplers of gap junctions; (ii) a low concentration of the NO donor sodium nitroprusside; and (iii) by the endothelin-receptor antagonist bosentan. It was also observed during contractions induced by (i) calcium channel activation (BayK 8644, 0.001-1 micromol x L(-1)); (ii) depolarization (10-40 mmol x L(-1) K(+)); and (iii) sympathetic nerve stimulation (0.25-32 Hz). CONCLUSIONS AND IMPLICATIONS: These pharmacological observations indicated feedback control by endothelium of ASM reactivity involving gap junctions and a balance between endothelium-derived NO and endothelin-1. This myoendothelial coupling was most prominent in distal resistance arteries.
BACKGROUND AND PURPOSE: We tested the hypothesis that activated arterial smooth muscle (ASM) stimulates endothelial vasomotor influences via gap junctions and that the significance of this myoendothelial coupling increases with decreasing arterial diameter. EXPERIMENTAL APPROACH: From WKY rats, first-, second-, third- and fourth-order branches of the superior mesenteric artery (MA1, MA2, MA3 and MA4 respectively) were isolated and mounted in wire-myographs to record vasomotor responses to 0.16-20 micromol x L(-1) phenylephrine. KEY RESULTS: Removal of endothelium increased the sensitivity (pEC(50)) to phenylephrine in all arteries. The nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) (100 micromol x L(-1)) did not modify pEC(50) to phenylephrine in all denuded arteries, and increased it in intact MA1, MA2 and MA3 to the same extent as denudation. However, in intact MA4, the effect of L-NAME was significantly larger (DeltapEC(50) 0.57 +/- 0.02) than the effect of endothelium removal (DeltapEC(50) 0.20 +/- 0.06). This endothelium-dependent effect of L-NAME in MA4 was inhibited by (i) steroidal and peptidergic uncouplers of gap junctions; (ii) a low concentration of the NO donorsodium nitroprusside; and (iii) by the endothelin-receptor antagonist bosentan. It was also observed during contractions induced by (i) calcium channel activation (BayK 8644, 0.001-1 micromol x L(-1)); (ii) depolarization (10-40 mmol x L(-1) K(+)); and (iii) sympathetic nerve stimulation (0.25-32 Hz). CONCLUSIONS AND IMPLICATIONS: These pharmacological observations indicated feedback control by endothelium of ASM reactivity involving gap junctions and a balance between endothelium-derived NO and endothelin-1. This myoendothelial coupling was most prominent in distal resistance arteries.
Authors: H Shimokawa; H Yasutake; K Fujii; M K Owada; R Nakaike; Y Fukumoto; T Takayanagi; T Nagao; K Egashira; M Fujishima; A Takeshita Journal: J Cardiovasc Pharmacol Date: 1996-11 Impact factor: 3.105
Authors: F R Stassen; M J Willemsen; G M Janssen; G E Fazzi; P M Schiffers; J F Smits; J G De Mey Journal: Br J Pharmacol Date: 1997-04 Impact factor: 8.739
Authors: M Clozel; V Breu; G A Gray; B Kalina; B M Löffler; K Burri; J M Cassal; G Hirth; M Müller; W Neidhart Journal: J Pharmacol Exp Ther Date: 1994-07 Impact factor: 4.030
Authors: K A Dora; P E Martin; A T Chaytor; W H Evans; C J Garland; T M Griffith Journal: Biochem Biophys Res Commun Date: 1999-01-08 Impact factor: 3.575
Authors: M J P M T Meens; N J A Mattheij; P B van Loenen; L J A Spijkers; P Lemkens; J Nelissen; M G Compeer; A E Alewijnse; J G R De Mey Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739
Authors: Pieter Lemkens; Leon Ja Spijkers; Merlijn J Meens; Jelly Nelissen; Ben Janssen; Stephan Lm Peters; Paul Mh Schiffers; Jo Gr De Mey Journal: Hypertens Res Date: 2017-03-16 Impact factor: 3.872
Authors: Merlijn J P M T Meens; Matthijs G Compeer; Tilman M Hackeng; Marc A van Zandvoort; Ben J A Janssen; Jo G R De Mey Journal: PLoS One Date: 2010-06-01 Impact factor: 3.240
Authors: Christopher J Kelsall; Samuel P Hoile; Nicola A Irvine; Mojgan Masoodi; Christopher Torrens; Karen A Lillycrop; Philip C Calder; Geraldine F Clough; Mark A Hanson; Graham C Burdge Journal: PLoS One Date: 2012-04-03 Impact factor: 3.240
Authors: Ramesh Chennupati; Merlijn J Meens; Ben J Janssen; Paul van Dijk; Theodorus B M Hakvoort; Wouter H Lamers; Jo G R De Mey; S Eleonore Koehler Journal: Physiol Rep Date: 2018-06